新型基因組乳癌檢測現已在美國推出
New Genomic Breast Cancer Test Now Available in the U.S.
Updated at: June 8, 2026 at 03:01 AM
癌症護理領域的一項重大進展已在美國實現。
A significant advancement in cancer care has arrived in the United States.
已正式推出Prosigna®乳癌復發風險（ROR）檢測。
This genomic tool is designed for patients diagnosed with early-stage, hormone-receptor-positive (HR+) breast cancer, representing a major shift toward personalized medicine.
這項基因檢測工具專為診斷出患有早期、荷爾蒙受體陽性（HR+）乳癌的患者設計，標誌著醫療邁向個人化的一大轉變。
Unlike traditional tests that focus on physical tumor characteristics, Prosigna uses advanced whole-transcriptome sequencing to analyze the specific genes within a tumor.
與著重於腫瘤物理特徵的傳統檢測不同，Prosigna利用先進的全轉錄體定序來分析腫瘤內部的特定基因。
By applying the PAM50 genomic classifier, the test generates a comprehensive risk score.
透過應用PAM50基因分類器，該檢測會產生一個全面的風險評分。
This data helps oncologists determine the likelihood of cancer recurrence over a decade, guiding crucial decisions on whether a patient truly needs chemotherapy or can safely rely on endocrine therapy alone.
此數據有助於腫瘤科醫師判斷未來十年間癌症復發的可能性，從而指導關鍵的決策，判斷患者是否確實需要化學治療，或者是否能單獨依賴內分泌治療。
With over 225,000 such cases diagnosed annually in the U.S., this technology is set to improve quality of life by sparing many patients from unnecessary, harsh treatments.
由於美國每年有超過225,000例這類病例確診，這項技術預計將能免除許多患者進行不必要的嚴酷治療，進而提升生活品質。
It is important to distinguish this from genetic testing; Prosigna examines existing tumor biology, not inherited mutations.
務必將此與遺傳檢測區分開來；Prosigna檢查的是現有的腫瘤生物學，而非遺傳突變。
Backed by recent clinical trials like the OPTIMA study, this launch marks a new era in tailoring cancer treatments to individual biological needs.
在OPTIMA研究等近期臨床試驗的支持下，此次發布標誌著根據個人生物學需求量身打造癌症治療的新紀元。
